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Purpose or Objective: The aim of this study was to 
investigate the patterns of failure after radiotherapy for 
pediatric intracranial ependymoma and their correlation to 
dose parameters. 
 
Material and Methods: Between 2000 and 2013, 206 patients 
with intracranial ependymoma were treated in the 13 french 
reference pediatric radiotherapy centers . The magnetic 
resonance imaging obtained at recurrence were registered 
with the original planning CT for topographic analysis of the 
patterns failure. Clinical target volume (CTV) and planning 
target volume (PTV) margins were extracted ; several 
dosimetric quality indices were derived from Dose Volume 
Histogram (DVH) to compare relapse with no-relapse patient. 
 
Results: With a median follow-up of 44.81 months (95% CI 
[36.80; 56.51]), 85 (41.3%) patients presented with 
recurrence. The topographic analysis of patterns of failure 
showed 50 (58.8%) patients with local recurrence in the 
radiation field (LF), 6 (4.1%) in the edge of field (EFG), 6 
(7.1%) were loco-regional outside the field (LRF), 8 (9.4%) in 
spine (SF), 5 supratentorial (SUF) and 10 (11.8%) local and 
distant (LDF). The median prescription dose was respectively: 
55.8 Gy [50.4; 60] in LF, 54 Gy [48.6; 59.4] in EF, 56.7 Gy 
[50.4; 60] in LRF, 54 Gy [50.4; 59.4] in LDF, 59.4 Gy [48.6-
59.4] in SUF and 56.7Gy [54; 60] in SF. The median PTV 
margins was 0.5 mm [0.3; 1]. The median Coverage index and 
The Target Coverage index of the PTV were both lower in the 
relapse group as they were respectively 0.97 and 94.8% in the 
relapse group compared with 0.98 and 95.99% in the no-
relapse group. The median Homogeneity index was 0.097 in 
the relapse group versus 0.091 in the no-relapse group. The 
median volume of relapse was 1.29 cc [0.11; 27] in the LF 
group, with a median dose of 58.81 Gy [50.86; 61.38]. 
 
Conclusion: In patients with intracranial ependymoma, local 
failure in the tumor bed was the major pattern of failure. 
The preliminary results showed that all dosimetric indices on 
the PTV were worse in the relapse group. Improving the 
coverage of target volume may be an effective way to reduce 
the local failures. Thus a complementary correlation of 
relapse patterns with dose parameters to PTV and organs at 
risks and the irradiation techniques is under statistical 
analysis and final results will be presented at the meeting. 
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Purpose or Objective: Since 2009 we launched a strategy for 
children with centrally reviewed MRI diagnosis of diffuse 
intrinsic pontine glioma (DIPG) implying the intravenous 
administration of vinorelbine with nimotuzumab –an anti-
EGFR monoclonal antibody- weekly, for a total of 12 weeks, 
during radiotherapy delivery of 54 Gy, 1.8 Gy/fraction daily. 
After radiotherapy completion, vinorelbine and nimotuzumab 
were administered any other week until tumor progression or 
for a total of two years. In the attempt to improve survival 
and quality of life of our children, a protocol amendment in 
July 2011 introduced re-irradiation at relapse/progression. 
 
Material and Methods: Local re-irradiation consisted of 19.8 
Gy, fractionated over 11 days. A 3DCRT with 5-6 coplanar 
beams was adopted with a beam geometry possibly not 
overlapping that of the first line irradiation; the most 
demanding planning issue of re-irradiation was to meet optic 
chiasm dose constraints. Three additional children were re-
irradiated to distant sites of relapse, spine (2) or ventricular 
system at doses of 36 Gy or 54 Gy respectively. 
Results: Of the 39 patients treated from 8/2009, 28 had local 
(23) or disseminated (5) progression and 18 were given local 
(15) or distant (3) relapse re-irradiation at a median of 8 
months after first radiotherapy (2.5-19 months). Reasons for 
not re-irradiating the other 10 children were: progression 
before July 2011 (4), parents refusal (4), too poor Lansky 
status (2); median PFS and progression site were not 
different in the two subgroups. Survival after re-irradiation 
lasted between two weeks and 14 months, median 6 months, 
and determined a statistically difference in median OS 
between the two groups of re-irradiated or not children, 
being 16 and 12 months, respectively (P=0.004). In 16 
radiologically evaluated patients, re-irradiation induced: 
reduction of tumor volume in 8, stable volume in 3 while 5 
had progression; 13 had symptom amelioration and 12 steroid 
suspension. Volume reductions were obtained in 7/8 children 
that have shown the same response after first line irradiation 
while one was obtained after stable disease in first line 
treatment. No adverse event was reported and all children 
were re-irradiated as outpatients . 
 
Conclusion: Re-irradiation after relapse/progression 
represented a significant benefit for both OS and quality of 
life of children with DIPG with symptom amelioration in 
13/18. This option is worth to be offered also in case of 
disseminated progression.  
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Purpose or Objective: For the treatment of adult patients 
newly diagnosed with medulloblastoma, there is no standard 
to guide multimodality therapy. With a multi-institutional 
cohort, we investigated and reported the multidisciplinary 
approach, clinical outcome, and prognostic factors of 
medulloblastoma in adult patients treated with postoperative 
radiotherapy (RT). 
 
